Comparative Pharmacology
Head-to-head clinical analysis: MECLAN versus TETRACHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLAN versus TETRACHEL.
MECLAN vs TETRACHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclizine is an antihistamine with central anticholinergic properties. It blocks histamine H1 receptors and exerts antiemetic effects via inhibition of the vestibular system and chemoreceptor trigger zone.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
250 mg orally three times daily for 7-14 days; for sinusitis: 500 mg three times daily.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours).
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Renal excretion of unchanged drug and metabolites: ~70%; fecal/biliary: ~30%.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic